Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Just under in terms of holding value vs. purchase price. Glad its over...
There is nothing forward-looking in my opinion. I have merely observed that the funding mechanism used to claw in revenue is expensive and the market has reacted accordingly. If you do think that one analyst/blogger/individual can sway markets and share prices, then perhaps this investing thing isn't for you...
That's an expensive method of buying revenue and with a funder notorious for charging top dollar for its money which in itself implies SBTX had/has very limited options. Market has read this correctly.
Two discussions/offers is better than one....
A few director deals, cash from divisional sale and performance within guidance. Points towards a more hopeful future but it has been a long time....
Have been travelling via BA and others recently. Load factors were over 90% for all flights taken (total of 8, of which 5 x BA).
Interesting letter from Sparta. Share buybacks only provide a temporary lift to share prices, if at all. Would be much better to invest money into improving the business longer term.
Good start to the year...not. Now at 2.41p - all sales so far today. At this rate it will be 2p by Monday.
Rupert needs to get this one over the line although £10.75 is apparently generous given Sky's performance as calculated by vysyble. They think that Sky is losing money and Fox are streamlining too. Big problem is football contract. Seems to be draining Sky with redundancies and cost-savings apparent.
Big buy methinks.
The science is still being proven so there will be aspects of the results that will fall outside of parameters that were agreed before the trial started. Generally, the news is good. The markets, however, like things to be perfect which this release does not quite achieve. What will be of interest is how RENE follows this up over the next few weeks as the underlying science appears to work but it is clear that they now have a PR job to do to allay any fears.
Ugly trading finish....
Another good release but its still all about the revenue....
No surprises on this release. I don't expect it to move out of range unless QM can build on its run of contracts achieved over the summer. Even then, the outstanding warrants will need to be cleared. Suspect that this will breakeven at best for next year or two as warrants are wound down before real growth takes place.
Revenue increase impressive as is the cash burn...They are taking an early hit in staffing up so it will be an interesting 6 months before full results to see if that investment is starting to pay off. Overall, looks OK for now. Has been a revenue story since 2014 and continues to be so.
it's starting to move. Needs to break and hold above 7.0p given previous history.
Simple - always helps to have a 'name' on the register so can imagine that GS were looking for an uptick on their investment by publicising their presence. As for longer-term intentions we shall have to wait and see.
Canadian horror story is costing the firm dear. Lot of big differentials y-on-yr on the balance sheet, most of them not good. Cash position is tricky. Totally reliant on China and Mexico to get their costs down given indicated demand in the report.
Great peer review paper published. Wound treatment times and outcomes significantly improved with TRX products. http://onlinelibrary.wiley.com/doi/10.1111/iwj.12667/full
Cash burn is high. Revenues holding but overall it's not a game changing proposition any more - they are now fearful of new competition. This firm has missed a good opportunity. and will suffer for it. Probable cash raise looming and it wouldn't surprise me if some of that were to come from selling off the family silver as well as a share dilution. Its a real pity as it had the tech but not the commercial brains.